Status:

COMPLETED

Complement C5 mAb in the Treatment of Anti-GBM Disease

Lead Sponsor:

Peking University First Hospital

Conditions:

Autoimmune Diseases

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

Anti-GBM disease is the most severe form of glomerulonephritis. Despite of the standard treatment including plasmapheresis and immunosuppressant, 70% of the patients still go into end-stage kidney dis...

Detailed Description

Anti-glomerular basement membrane (anti-GBM) disease is the most severe form of autoimmune glomerulonephritis, characterized by the production of autoantibodies targeting the components of basement me...

Eligibility Criteria

Inclusion

  • Inclusion Criteria
  • Positive circulating anti-GBM antibody, with proteinuria or hematuria or any clinical signs of kidney injuries.
  • And or kidney biopsy showed typical IgG linear deposition along the GBM
  • At least 18 years old
  • Exclusion Criteria
  • Allergic to eculizumab, mouse protein or the investigational drug and any of its excipients;
  • Uncontrolled meningococcal infection,or those who have not received meningitis prophylactic antibiotic treatment or meningitis vaccination;
  • Diagnosis of anti-GBM disease for more than 12 weeks before signing the informed consent form;
  • Pregnant or lactating
  • Received investigational drug within 30 days or 4 half-lives (whichever is longer) prior to screening;
  • Other serious poorly controlled comorbid diseases that affect the compliance of the trial protocol or the interpretation of results within 3 months prior to screening, including cardiovascular and cerebrovascular diseases, lung disease, etc.;
  • Presence of any medical history or disease that, in the opinion of the investigator, may expose the patient's participation in the study to an unacceptable risk;

Exclusion

    Key Trial Info

    Start Date :

    March 1 2024

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    November 3 2025

    Estimated Enrollment :

    16 Patients enrolled

    Trial Details

    Trial ID

    NCT06513338

    Start Date

    March 1 2024

    End Date

    November 3 2025

    Last Update

    December 5 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Peking University First Hospital

    Beijing, China, 100038